CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
ambrisentandrug
Likely dose
ambrisentan 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01330108
NCT01330108Phase 4Completed
CompareCT.gov

Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension

University of Alabama at Birmingham·interventional·Posted Apr 6, 2011·Updated Aug 11, 2014

In Brief

A Phase 4 clinical trial evaluating ambrisentan for Pulmonary Arterial Hypertension. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 6, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.2 years ago

Interventions

ambrisentandrug

ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.